share_log

Maxim Group Initiates Coverage On NeuroBo Pharmaceuticals With Buy Rating, Announces Price Target of $10

Maxim Group Initiates Coverage On NeuroBo Pharmaceuticals With Buy Rating, Announces Price Target of $10

Maxim集团以买入评级启动对NeuroBO制药的报道,宣布目标股价为10美元
Benzinga ·  05/08 10:08

Maxim Group analyst Jason McCarthy initiates coverage on NeuroBo Pharmaceuticals (NASDAQ:NRBO) with a Buy rating and announces Price Target of $10.

Maxim集团分析师杰森·麦卡锡以买入评级启动了对NeuroBo Pharmicals(纳斯达克股票代码:NRBO)的报道,并宣布目标股价为10美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发